June 11, 2020 / 12:34 PM / a month ago

BRIEF-Intelgenx Says Got Clarity From FDA On CMC Information Required For Resubmission Of NDA For Acute Migraines Treatment

June 11 (Reuters) - Intelgenx Technologies Corp:

* INTELGENX PROVIDES UPDATE ON RIZAPORT® VERSAFILM® NDA RESUBMISSION PROCESS FOLLOWING TYPE A MEETING WITH THE FDA

* INTELGENX TECHNOLOGIES CORP - OBTAINED CLARITY FROM FDA ON CMC INFORMATION REQUIRED FOR RESUBMISSION OF NDA FOR ACUTE MIGRAINES TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below